c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity.The mature receptor is made up of the alpha and beta subunits, which are disulfide linked after post-translational cleavage of the primary single chain precursor protein. A membrane receptor called c-Met is crucial for both wound healing and embryonic development. The c-Met receptor's sole known ligand is hepatocyte growth factor (HGF). Cells of epithelial origin typically express c-Met, whereas cells of mesenchymal origin only express HGF. In response to HGF stimulation, c-Met triggers a number of biological processes that together give rise to the invasive growth program.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V78395 | MET/PDGFRA-IN-2 | MET/PDGFRA-IN-2 (compound 8h) is an inhibitor (blocker/antagonist) of MET and PDGFRA proteins. | |
|
V4303 | MK8033 | 1001917-37-8 | MK-8033 is a novel, potent, selective, ATP competitive small-molecule, dual inhibitor of c-Met/Ron (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer. |
|
V4304 | MK8033 HCL | 1283000-43-0 | MK-8033 HCl is a novel, potent, selective, ATP competitive small-molecule, dual inhibitor of c-Met/Ron (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer. |
|
V0597 | NVP-BVU972 | 1185763-69-2 | NVP-BVU972 (also names as BVN972; BVN-972) is a novel c-Met inhibitor with potential anticancer activity. |
|
V69299 | Onartuzumab (MetMAb) | 1133766-06-9 | Onartuzumab (MetMAb) is a humanized affinity matured monovalent monoclonal antibody (mAb) that can inhibit the receptor tyrosine kinase MET. |
|
V0603 | PF-04217903 | 956905-27-4 | PF-04217903 (PF04217903) is an orally bioavailabe and ATP-competitivesmall-molecule inhibitor of the tyrosine kinase c-Met with potential antitumor activity. |
|
V4454 | PF-04217903 mesylate | 956906-93-7 | PF-04217903 mesylate, the methanesulfonate salt of PF-04217903, is a novel, potent, orally bioavailabe, selective, and ATP-competitive small-molecule tyrosine kinase inhibitor of c-Met with IC50 of 4.8 nM in A549 cell line and with anticancer activity, it is susceptible to oncogenic mutations (with no activity to Y1230C mutant). |
|
V39597 | PF-04217903 phenolsulfonate | 1159490-85-3 | PF-04217903 phenolsulfonate is a novel, highly potent and ATP-competitive inhibitor of c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met and has antiangiogenic properties. |
|
V0591 | PHA-665752 | 477575-56-7 | PHA-665752 (PHA665752) is a novel, potent, selective and ATP-competitive small molecule inhibitor of c-Met Kinase with potential antitumor activity. |
|
V69316 | Resencatinib | 2546117-79-5 | Resencatinib is a potent tyrosine kinase inhibitor (antagonist) with anticancer effect. |
|
V69305 | Rilotumumab (AMG 102) | 872514-65-3 | Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody (mAb) that can inhibit HGF/MET-driven signaling. |
|
V69313 | Risvodetinib (IkT-148009) | 2031185-00-7 | Risvodetinib is a potent protein tyrosine kinase inhibitor. |
|
V7192 | RON-IN-1 (AMG-1) | 913376-84-8 | SYN1143 is a potent, selective and orally bioactive dual c-Met/RON inhibitor (antagonist) with IC50s of 4 and 9 nM, respectively. |
|
V2150 | S-49076 | 1265965-22-7 | S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3. |
|
V3475 | SAR125844 | 1116743-46-4 | SAR125844 is a novel, potent, highly selective, reversible and ATP-competitive inhibitor ofMET receptor tyrosine kinase (RTK)for intravenous administration, with anIC50of 4.2 nM. |
|
V3132 | Savolitinib (AZD6094, HMPL-504) | 1313725-88-0 | Savolitinib (volitinib, AZD-6094, HMPL-504; Orpathys; HUTCHMED) is a novel, potent, orally bioactive and selective inhibitor of the c-Met receptor kinase with anticancer activity. |
|
V2988 | SCR-1481B1 | 1174161-86-4 | SCR-1481B1 (also known as c-Met inhibitor 2) is a novel potent and selective MET inhibitor. |
|
V0593 | SGX-523 | 1022150-57-7 | SGX-523 (SGX 523;SGX523) is a novel, exquisitely selective, and ATP-competitive inhibitor of Hepatocyte growth factor receptor/Met with potential anticancer activity. |
|
V0592 | SU11274 (PKI SU11274; PKI SU11274) | 658084-23-2 | SU11274 (also called PKI-SU11274; PKI-SU-11274) is a novel, potent and selective Met inhibitor with potential antineoplastic activity. |
|
V0596 | Tepotinib (EMD 1214063; MSC 2156119) | 1100598-32-0 | This product has been discontinued. Tepotinib (formerly EMD 1214063, EMD-1214063; MSC2156119; MSC-2156119; Tepmetko) is a selective c-Met inhibitor with potential antineoplastic activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
